Zyrtec-D

Version NCDSv04
Zyrtec D

Name of The Medicinal Product

ZYRTEC-D 5mg/120 mg, prolonged-release tablet

Qualitative and Quantitative Composition

ZYRTEC-D 5mg/120 mg, prolonged-release tablet
Each tablet contains 5 mg cetirizine dihydrochloride in an immediate release form and 120 mg pseudoephedrine hydrochloride in a prolonged-release form.

Excipients

ZYRTEC-D 5mg/120 mg, prolonged-release tablet
Hypropemllose, Microcrystalline cellulose, Colloidal anhydrous silica, Magnesium stearate, Lactose monohydrate, Croscarmellose sodium, Titanium dioxide (E171), Macrogol 400.

Pharmaceutical Form

ZYRTEC-D, 5mg/120 mg, prolonged-release tablet
Prolonged release tablet is white to off-white, round, biconvex film-coated tablet having a circular logo on one side.

Clinical Information

Indications

ZYRTEC-D is indicated for symptomatic treatment of acute rhinitis with nasal congestion and hypersecretion, nose and/or eye itching and watery eyes.

It should be administered when both the anti-allergic properties of cetirizine dihydrochloride and the nasal decongestant activity of pseudoephedrine hydrochloride are desired.

Dosage and Administration

The tablet should be swallowed whole with some liquid, and must not be broken, chewed or crushed. It may be taken with or without food.

The duration of treatment should not exceed the period of acute symptoms and should not exceed 2 - 3 weeks. After improvement of nasal symptoms, treatment should be continued only with cetirizine, where appropriate.

Route of Administration

For oral use.

Adults and Children Aged 12 Years and Older

One tablet twice daily (morning and evening).

Children Under 12 Years of Age

ZYRTEC-D is contraindicated in children under 12 years of age (see Sections: Contraindications; Warnings and Precautions).

Elderly

No data.

Renal Impairment

The dose should be reduced to one tablet daily in patients with moderate renal insufficiency. Cetirizine/ pseudoephedrine is contraindicated in severe renal insufficiency (see Section Contraindications).

Hepatic Impairment

The dose should be reduced to one tablet daily in patients with moderate hepatic insufficiency.

Contraindications

ZYRTEC-D is contraindicated in:

- known hypersensitivity to the active substances or excipients, to ephedrine or any other piperazine,
- severe hypertension or severe ischemic heart disease,
- severe renal insufficiency,
- uncontrolled hyperthyroidism,
- severe arhythmias,
- pheochromocytoma,
- elevated intraocular pressure,
- urinary retention,
- glaucoma,
- history of stroke
- high risk of haemorrhagic stroke (see Section Warnings and Precautions),
- concomitant administration of dihydroergotamine (see Section Interactions),
- concomitant treatment with MAOI and within 2 weeks after their discontinuation (see Section Interactions),
- children under 12 years of age (see Section Warnings and Precautions).

Warnings and Precautions

General Precautions

Due to the presence of pseudoephedrine, ZYRTEC-D should be used with caution in patients with diabetes mellitus, hyperthyroidism, arterial hypertension, tachycardia, cardiac arrhythmia, ischaemic heart disease, moderate hepatic or renal insufficiency, and also in the elderly.

Caution is also required in patients taking:

- sympathomimetics including decongestants, anorexogenic substances or psychostimulants such as amphetamines (combined effects on the cardiovascular system),
- tricyclic antidepressants,
- antihypertensive drugs (reduction of antihypertensive effects) (see Section Interactions),
- alcohol and other CNS depressants (increased depressive action on the CNS and reduced performance),
- cardiac glycosides such as digoxin or digitin (risk of cardiac arrhythmias) (see Section Interactions),
- as well as in conditions where an anticholinergic action should be avoided, like in cases of prostatic hypertrophy or urinary obstruction.

Posterior Reversible Encephalopathy (Pres)/Reversible Cerebral Vasocstruction Syndrome (RCVS)

There have been rare cases of posterior reversible encephalopathy (PRES)/reversible cerebral vasocstruction syndrome (RCVS) reported with sympathomimetic drugs, including pseudoephedrine. Symptoms reported included sudden onset of severe headache, nausea, vomiting, and visual disturbances. Most cases improved or resolved within a few days following appropriate treatment. Pseudoephedrine should be discontinued immediately and medical advice sought if signs/symptoms of PRES/RCVS develop.

Vasoconstrictor Effect

Caution should also be taken in patients with factors which could increase the risk of haemorrhagic stroke, (concomitant use of vasoconstrictors such as bromocriptine, pergolide, lisuride, cabergoline, ergotamine), or any other decongestant drug used as nasal decongestant, either by oral route or by nasal route (phenylephrine, phylephrine, ephedrine), due to the risk of vasoconstriction and increased blood pressure.

Due to vasoconstrictor effect of pseudoephedrine, caution is recommended in patients who are at risk for hypercoagulability, as in inflammatory bowel disease (see Section Interactions).

Use with NSAIDs In Hypertensive Patients

Caution is required in hypertensive patients who are treated concomitantly with NSAIDs, because both pseudoephedrine and NSAIDs can increase blood pressure.

Cases of Abuse

As with centrally acting stimulants, cases of abuse have been observed with pseudoephedrine.

Children Under 12 Years of Age

ZYRTEC-D is contraindicated in children under 12 years of age due to the presence of pseudoephedrine and because this combination has not been studied in this age group (see Section Contraindications).

Lactose

ZYRTEC-D, 5mg/120 Mg, Prolonged-Release Tablet

This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Interactions

No interaction studies have been performed with the combination cetirizine-pseudoephedrine.

Lack of Interactions

Pharmacokinetic interaction studies were conducted with cetirizine and cimetidine, ketoconazole, erythromycin, azithromycin, antipyrine and pseudoephedrine; no pharmacokinetic interactions were observed.

Studies with cetirizine and cimetidine, glipizide, dazaepam, and pseudoephedrine have revealed no evidence of adverse pharmacodynamic interactions.

Studies with cetirizine and azithromycin, erythromycin, ketoconazole, theophylline, antipyrine and pseudoephedrine have revealed no evidence of adverse clinical interactions. In particular, concomitant administration of cetirizine with macrolides or ketoconazole has never resulted in clinically relevant ECG changes.

Theophylline

In a multiple dose study of theophylline (400 mg once a day) and cetirizine, there was a small (16%) decrease in clearance of cetirizine, while the elimination of theophylline was not altered by concomitant cetirizine administration.

Ritonavir

In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the elimination of ritonavir was slightly altered (-11%) by concomitant cetirizine administration.

Mao Inhibitors

Concomitant use of sympathomimetic amines with monoamine oxidase (MAO) inhibitors can result in hypertensive crisis. Due to the long duration of action of MAO inhibitors, this interaction is still possible 15 days after discontinuation of their administration (see Section Contraindications).

Linezolid

Concomitant administration of linezolid and pseudoephedrine can increase arterial pressure in normotensive patients.

Reduction of The Antihypertensive Effects of Drugs

Sympathomimetic amines may reduce the antihypertensive effects of beta-adrenergic blockers and of drugs that interfere with sympathetic nervous system activity such as methyldopa, guanethidine and reserpine (see Section Warnings and Precautions).

Cardiac Glycosides

The ectopic pacemaker activity can be increased when pseudoephedrine is used with cardiac glycosides, such as digoxin or digitin; the use of cetirizine/pseudoephedrine, therefore should be avoided in patients treated with cardiac glycosides.

Drugs Increasing or Decreasing Cetirizine/Pseudoephedrine Absorption

Antacids and proton pump inhibitors increase the absorption of pseudoephedrine, kaolin reduces absorption.
Halogenated Anaesthetic Agents
Concurrent use with halogenated anaesthetic agents may provoke or worsen ventricular arrhythmia.

Allergy Tests
Antihistamines can interfere with allergy tests and an appropriate wash-out period is required before conducting such tests.

Fat Meal
A high-fat meal was not found to modify the bioavailability of both active ingredients, but it resulted however in a reduced and delayed peak plasma concentration of cetirizine.

Pregnancy and Lactation
Fertility
A study in animals has demonstrated that the combination of cetirizine/ pseudoephedrine (1:24) has no impact on fertility at a dose of up to 10 times the recommended dose. There are no available data on fertility in humans.

Pregnancy
ZYRTEC® should not be used during pregnancy.

There are no adequate data on the use of cetirizine/pseudoephedrine in pregnant women. The use of pseudoephedrine during the first trimester of pregnancy has been associated with an increased frequency of gastrochisis (a developmental defect in the abdominal wall with intestinal herniation) and of small bowel atresia (congenital obstruction of small bowel).

Due to the vasoconstrictive properties of pseudoephedrine, this product should not be used during the third trimester of pregnancy as it can induce a retardation in uteroplacental circulation. Data on a limited number of exposed pregnancies indicate no adverse effects of cetirizine on pregnancy or on the health of the foetus/newborn child. There is insufficient animal data with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.

Lactation
ZYRTEC® should not be used during breastfeeding.

Cetirizine and pseudoephedrine are excreted into human milk.

Ability to Perform Tasks That Require Judgement, Motor or Cognitive Skills
Patients intending to drive, engaging in potentially hazardous activities or operating machines should not exceed the recommended dose and should take their individual response to the medicinal product into account. However, it should be noted that the effects of these drugs may vary depending on the individual response: clinical studies have shown cases of drowsiness. Effects on the central nervous system may occur with doses higher than those usually recommended. If patients experience drowsiness or vertigo, they should not drive.

Objective measurements of driving ability, sleep latency and assembly line performance, following the administration of cetirizine, have not demonstrated any clinically relevant effects at the recommended dose of 10 mg/day. No negative effects associated with the use of pseudoephedrine have been reported and are expected to occur.

Concurrent use of cetirizine with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.

Adverse Reactions
Clinical Trial Data
In controlled clinical trials, adverse reactions reported in more than 1 % of the patients receiving the combination cetirizine/pseudoephedrine, were not different from those reported for cetirizine or pseudoephedrine alone.

Post Marketing Data
Undesirable effects encountered with cetirizine are mainly related to CNS depressant or paradoxical CNS stimulation effects, to anticholinergic-like activity or hypersensitivity reactions (including anaphylactic shock), while the undesirable effects of pseudoephedrine are more likely related to CNS stimulation, and cardiovascular disorders. Cases of abnormal hepatic function with increased hepatic enzymes levels, accompanied by elevated bilirubin, where reported; the majority of the cases were resolved after interrupting the treatment with cetirizine/dihydrochloride. Isolated cases of stroke and ischemic colitis associated with pseudoephedrine use have been identified in literature.

Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency.

Frequencies are defined as:
- Very common: ≥1/10
- Common: ≥1/100 to <1/10
- Uncommon: ≥1/1000 to <1/100
- Rare: ≥1/10000 to <1/1000
- Very rare: <1/10000
- Not known: (cannot be estimated from the available data).

Imune System Disorders
- Rare: hypersensitivity

Psychiatric Disorders
Common: nervousness, insomnia
Uncommon: anxiety, agitation
Rare: hallucination
Very rare: psychotic disorder

Nervous System Disorders
Common: vertigo, dizziness, headache, somnolence
Rare: convulsions, tremor
Very rare: dysequia, cerebrovascular accident (stroke)

Eye Disorders
Not known: accommodation disorder, vision blurred, mydriasis, eye pain, visual impairment, photophobia

Cardiac Disorders
Common: tachycardia
Rare: arrhythmia

Vascular Disorders:
- Rare: pallor, hypertension
- Very rare: circulatory collapse

Respiratory, Thoracic and Mediastinal Disorders
- Not known: dyspnoea

Gastrointestinal Disorders
Common: dry mouth, nausea
Rare: vomiting
Very rare: colitis ischaemic

Hepatobiliary Disorders
- Rare: hepatic function disorders (increase in transaminases, alkaline phosphatase, gamma-GT, bilirubin)

Skin and Subcutaneous Tissue Disorders
- Rare: dry skin, rash, hyperhidrosis, urticaria
- Very rare: fixed drug eruption, angioneurotic oedema

Renal and Urinary Disorders
Rare: dysuria

Reproductive System and Breast Disorders
- Not known: erectile dysfunction

General Disorders and Administration Site Conditions
Common: asthenia

Overdosage
Symptoms and Signs
Cetirizine
Symptoms observed after an overdose of cetirizine are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect.

Pseudoephedrine
In large doses, sympathomimetics may induce a toxic psychosis with delusions and hallucinations. Some patients may develop cardiac arrhythmia, circulatory collapse, convulsions, coma, and respiratory failure, which can be fatal.

Cetirizine/Pseudoephedrine
Acute overdose with cetirizine/ pseudoephedrine may cause diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, urinary retention, tachycardia, cardiac arrhythmia, arterial hypertension, signs of CNS depression (sedation, apnoea, unconsciousness, cyanosis and cardiovascular collapse) or CNS stimulation (osmoincre, hallucinations, tremor, seizures) which could be fatal.

Treatment
Treatment, preferably given in hospital, should be symptomatic and supportive. Consideration should be given to the possible concomitant ingestion of other drugs. If spontaneous vomiting does not occur, it should be induced.

Cetirizine and pseudoephedrine are poorly eliminated by haemodialysis.

Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

Clinical Pharmacology
Pharmacodynamics
Pharmacotherapeutic Group
Nasal decongestants for systemic use.

ATC Code
R01BA52

Mechanism of Action and Pharmacodynamic Effects
The pharmacodynamic activity of cetirizine – pseudoephedrine is directly related to the additive effect of the action of its constituents.

Cetirizine
Cetirizine is a potent and selective antagonist of the H1-receptor with anti-allergic properties; it inhibits the early phase of the histamine-related allergic reaction; in addition it reduces the migration of some type of inflammatory cells and the release of mediators associated with the late allergic response; it inhibits the reactions induced by histamine and pollens in nasal provocative tests.

Pseudoephedrine
Pseudoephedrine, a stereoisomer of ephedrine, is an orally active sympathomimetic, whose alpha-mimetic effects are greater than its beta-mimetic activity; due to its vasoconstrictor action, it has a decongestant effect on the nasal mucosa.

Pharmacokinetics
There was no evidence for a relevant pharmacokinetic interaction between cetirizine and pseudoephedrine.

Absorption and Distribution
Cetirizine
After oral administration, cetirizine is rapidly and almost completely absorbed. Peak plasma concentrations are generally obtained within 1 hour under fasting conditions. The absorption is independent of the dose.
Inter- and intra-subject variations are low. Cetirizine is highly bound to plasma proteins (93%). Its volume of distribution is small: approximately 0.5 l/kg.

Pseudoephedrine

Pseudoephedrine given as the sustained-release formulation cetirizine/ pseudoephedrine provides maximum plasma levels 2 to 6 hours after multiple dosing.

Metabolism and Elimination

Cetirizine

Cetirizine does not undergo any appreciable first pass metabolism. The plasma half-life of cetirizine is approximately 9 hours. This value is increased in patients with reduced renal function. After repeated oral administration, the daily urinary excretion of unchanged cetirizine is approximately 65 % of the dose. The elimination is independent of the dose.

Pseudoephedrine

It is excreted mainly unchanged in the urine. The rate of urinary excretion is increased when the pH of urine is reduced, and reduced in case of alkalization of urine. After repeated oral administration (every 12 hours), at steady-state, the apparent elimination half-life is estimated to be approximately 9 hours.

Special Patient Populations

Renal Impairment

The dose should be reduced to half the usual recommended dose.

Clinical Studies

Not relevant for this product. Non-Clinical Information

Animal studies have shown no toxic for doses equal or higher than 30 mg/kg/day in rats and 40 mg/kg/day in the Cynomolgus monkey (2.8 and 11 times the recommended dose in humans). The systemic exposure to these doses was higher in the monkey but lower in rats, compared to that obtained in humans. Reproduction toxicology studies in rats showed no effects at a dose of 40 mg/kg/day. Due to the low levels of systemic exposure in this species, these results cannot be considered significant to demonstrate a safe use in pregnant and lactating women.

Cetirizine/ pseudoephedrine is neither mutagenic nor clastogenic and therefore this combination likely presents no risk of carcinogenicity in humans.

In reproduction toxicology studies, fertility in male and female rats was unimpaired at doses up to 180 mg/kg/day (1:24), which represents an estimated systemic exposure to pseudoephedrine 10 times higher than the therapeutic exposure in humans.

Pharmaceutical Information

Shelf-Life

Note for GSK operating companies:
The country PI must include statement(s) in accordance with data in the registered CMC dossier.

Storage

Note for GSK operating companies:
The country PI must include statement(s) in accordance with data in the registered CMC dossier.

Nature and Contents of Container

Note for GSK operating companies:
The country PI must include statement(s) in accordance with data in the registered CMC dossier.

Incompatibilities

There are no relevant data available.

Use and Handling

There are no special requirements for use or handling of this product